^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    perzebertinib (RG6596)

    i
    Other names: RG6596, ZN-A-1041, ZN-1041, RG 6596, ZN 1041, ZN A 1041, RG-6596, ZN1041, ZNA1041, RO7771950, RO-7771950
    Company:
    Roche, Suzhou Zanrong
    Drug class:
    HER2 inhibitor
    Related drugs:
    1m
    BReNNA: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive (clinicaltrials.gov)
    P2/3, N=650, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • perzebertinib (RG6596)
    1m
    A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov)
    P1, N=24, Completed, Genentech, Inc. | Recruiting --> Completed | N=48 --> 24 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    perzebertinib (RG6596)
    1m
    WO46069: A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in Combination with Trastuzumab and Capecitabine, in People with Locally Advanced or Metastatic Breast Cancer that is HER2-Positive (2025-524498-17-00)
    P2/3, N=107, Not yet recruiting, F. Hoffmann-La Roche AG
    New P2/3 trial
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • perzebertinib (RG6596)
    3ms
    A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, Genentech, Inc. | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    perzebertinib (RG6596)
    4ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    4ms
    BReNNA: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive (clinicaltrials.gov)
    P2/3, N=650, Not yet recruiting, Hoffmann-La Roche
    New P2/3 trial
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • perzebertinib (RG6596)
    5ms
    A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, Genentech, Inc.
    New P1 trial
    |
    perzebertinib (RG6596)
    6ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2026 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    8ms
    A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants (clinicaltrials.gov)
    P1, N=18, Completed, Genentech, Inc. | Recruiting --> Completed | N=66 --> 18 | Trial completion date: Oct 2025 --> Jul 2025 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    perzebertinib (RG6596)
    9ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Phase classification: P1 --> P1/2
    Enrollment closed • Phase classification
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    10ms
    ZN-1041-101: Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=61, Completed, Suzhou Zanrong Pharma Limited | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • perzebertinib (RG6596)
    11ms
    A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants (clinicaltrials.gov)
    P1, N=66, Recruiting, Genentech, Inc.
    New P1 trial
    |
    perzebertinib (RG6596)